HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Bruno Sangro Selected Research

Sirtuins

4/2024Predictive value of platelet-to-lymphocyte and neutrophil-to-lymphocyte ratio in HCC treated with sorafenib and radioembolization.
1/2023Defining textbook outcome for selective internal radiation therapy of hepatocellular carcinoma: an international expert study.
11/2022Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study.
9/2022Gadoxetic acid uptake as a molecular imaging biomarker for sorafenib resistance in patients with hepatocellular carcinoma: a post hoc analysis of the SORAMIC trial.
1/2022A Simple Prognostic Scoring System for Hepatocellular Carcinoma Treated with Selective Internal Radiation Therapy.
1/2022A new animal model of atrophy-hypertrophy complex and liver damage following Yttrium-90 lobar selective internal radiation therapy in rabbits.
1/2022Extracellular Vesicles May Predict Response to Radioembolization and Sorafenib Treatment in Advanced Hepatocellular Carcinoma: An Exploratory Analysis from the SORAMIC Trial.
12/2021Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma.
1/20213D voxel-based dosimetry to predict contralateral hypertrophy and an adequate future liver remnant after lobar radioembolization.
8/2020The Pattern of Progression Defines Post-progression Survival in Patients with Hepatocellular Carcinoma Treated with SIRT.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Bruno Sangro Research Topics

Disease

99Neoplasms (Cancer)
01/2024 - 01/2002
95Hepatocellular Carcinoma (Hepatoma)
04/2024 - 01/2002
21Liver Neoplasms (Liver Cancer)
12/2023 - 06/2002
14Neoplasm Metastasis (Metastasis)
01/2023 - 06/2002
13Fibrosis (Cirrhosis)
07/2022 - 01/2002
9Colorectal Neoplasms (Colorectal Cancer)
12/2022 - 06/2002
9Liver Cirrhosis (Hepatic Cirrhosis)
06/2021 - 06/2005
8Cholangiocarcinoma
02/2024 - 09/2017
7Inflammation (Inflammations)
04/2024 - 05/2015
7Liver Diseases (Liver Disease)
02/2022 - 03/2011
7Infections
01/2019 - 01/2002
6Hepatitis
01/2024 - 10/2011
6Disease Progression
11/2022 - 06/2015
6Ascites
01/2021 - 04/2008
5Carcinoma (Carcinomatosis)
04/2018 - 10/2002
4Hepatitis C
02/2021 - 10/2016
3Hypertrophy
01/2022 - 05/2015
3Virus Diseases (Viral Diseases)
01/2021 - 01/2015
3Neuroendocrine Tumors (Neuroendocrine Tumor)
04/2018 - 09/2017
3Portal Hypertension
10/2017 - 06/2005
3Thrombosis (Thrombus)
05/2015 - 08/2010
3Pancreatic Neoplasms (Pancreatic Cancer)
07/2013 - 04/2004
2Colitis
01/2024 - 01/2024
2Carcinogenesis
05/2022 - 01/2021
2Pathologic Constriction (Stenosis)
01/2022 - 06/2020
2Hepatitis B
11/2020 - 01/2016
2Renal Cell Carcinoma (Grawitz Tumor)
01/2018 - 11/2014
2Skin Neoplasms (Skin Cancer)
03/2017 - 09/2005
2Melanoma (Melanoma, Malignant)
03/2017 - 11/2014
2Chronic Hepatitis C
01/2015 - 07/2013
2Liver Failure
04/2008 - 03/2003

Drug/Important Bio-Agent (IBA)

27Sorafenib (BAY 43-9006)FDA Link
04/2024 - 04/2010
21Yttrium-90IBA
02/2024 - 06/2007
16SirtuinsIBA
04/2024 - 01/2012
12Biomarkers (Surrogate Marker)IBA
12/2023 - 11/2014
10Immune Checkpoint InhibitorsIBA
01/2024 - 06/2017
9NivolumabIBA
01/2023 - 06/2017
8BilirubinIBA
12/2022 - 09/2011
7AlbuminsIBA
12/2022 - 10/2005
6Proteins (Proteins, Gene)FDA Link
02/2022 - 10/2002
6Monoclonal AntibodiesIBA
01/2021 - 08/2005
6Antiviral Agents (Antivirals)IBA
01/2021 - 07/2013
5tremelimumabIBA
12/2023 - 07/2011
5AntigensIBA
01/2021 - 10/2002
5Interleukin-12 (IL 12)IBA
12/2005 - 06/2002
4EnzymesIBA
04/2024 - 10/2006
4durvalumabIBA
12/2023 - 01/2021
4IpilimumabIBA
01/2023 - 07/2011
4VaccinesIBA
01/2022 - 10/2002
4alpha-Fetoproteins (alpha-Fetoprotein)IBA
01/2022 - 09/2011
4YttriumIBA
01/2018 - 01/2010
4ProdrugsIBA
01/2007 - 06/2002
3LipidsIBA
01/2023 - 06/2020
3Interleukin-6 (Interleukin 6)IBA
05/2022 - 06/2021
3Peptides (Polypeptides)IBA
01/2022 - 10/2002
3DNA (Deoxyribonucleic Acid)IBA
10/2021 - 06/2017
3Long Noncoding RNAIBA
10/2021 - 10/2019
3Interleukin-8 (Interleukin 8)IBA
06/2021 - 08/2005
3Hormones (Hormone)IBA
04/2018 - 10/2005
3ChemokinesIBA
11/2014 - 08/2005
3Thymidine KinaseIBA
06/2005 - 01/2002
2Cell-Free Nucleic AcidsIBA
12/2023 - 01/2022
2atezolizumabIBA
12/2023 - 01/2022
2Bevacizumab (Avastin)FDA Link
12/2023 - 01/2022
2Cytochrome P-450 Enzyme System (Cytochrome P450)IBA
01/2023 - 01/2023
2Glycine (Aminoacetic Acid)FDA LinkGeneric
05/2022 - 01/2019
2Glucose (Dextrose)FDA LinkGeneric
05/2022 - 09/2011
2Fatty Acids (Saturated Fatty Acids)IBA
11/2021 - 09/2011
2Irinotecan (Camptosar)FDA LinkGeneric
01/2021 - 01/2020
2OvalbuminIBA
11/2020 - 11/2013
2Neoplasm Antigens (Tumor Antigens)IBA
03/2019 - 10/2002
2InterferonsIBA
01/2019 - 10/2016
2erucylphosphocholineIBA
10/2017 - 10/2011
2Mycophenolic Acid (Cellcept)FDA LinkGeneric
03/2017 - 09/2004
2CytokinesIBA
07/2013 - 10/2011
2CD40 Ligand (CD40L)IBA
10/2011 - 06/2002
2Ganciclovir (Cytovene)FDA LinkGeneric
03/2003 - 06/2002
1LipopolysaccharidesIBA
04/2024
1CholesterolIBA
04/2024
1Circulating Tumor DNAIBA
12/2023
1Histone MethyltransferasesIBA
10/2023
1mRNA VaccinesIBA
01/2023
1COVID-19 VaccinesIBA
01/2023
119,20-epoxydocosapentaenoic acidIBA
01/2023
1Epoxy Compounds (Epoxides)IBA
01/2023

Therapy/Procedure

64Therapeutics
04/2024 - 01/2002
32Microspheres (Microsphere)
02/2024 - 11/2006
26Radiotherapy
04/2024 - 01/2009
22Immunotherapy
12/2023 - 06/2002
13Drug Therapy (Chemotherapy)
01/2021 - 01/2002
12Liver Transplantation
12/2021 - 11/2003
5Catheters
01/2020 - 07/2009
4Transplantation
01/2023 - 10/2014
4Aftercare (After-Treatment)
12/2021 - 04/2008
3Injections
12/2005 - 04/2004
2Hepatectomy
04/2024 - 05/2022
2Ligation
10/2021 - 01/2013
2Combined Modality Therapy
01/2018 - 06/2011
2Cell- and Tissue-Based Therapy (Cell Therapy)
10/2011 - 04/2004
1Length of Stay
01/2023